BioPharma Dive 14 ene 2026 Caldera starts up with $112.5M and a dual-targeting immune drug from China
BioPharma Dive 12 ene 2026 JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
BioPharma Dive 12 ene 2026 AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
BioPharma Dive 12 ene 2026 Best practices for COA selection: Building a stronger foundation for clinical trials
BioPharma Dive 9 ene 2026 Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies